» Articles » PMID: 24392455

Hsa-miR-15a and Hsa-miR-16-1 Expression is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is the commonest leukemia in adults. Here, we aimed to evaluate hsa-miR-15a/hsa-miR-16-1 expression in CLL tissues by qPCR and correlate it with the other clinicopathological features and clinical outcome. 40 formalin-fixed paraffin-embedded (FFPE) lymph node samples obtained from CLL/SLL patients were classified into two categories, "PCs rich" and "typical." We found a significant common expression level of 4 miRNAs; however, we did not find any significant relationship between PCs presence and miRNAs expression. Moreover, neither the presence of 13q deletion nor the percentage of cells carrying the deletion strictly correlated with miRNAs expression levels, although a significant number of patients with 13q deletion presented hsa-miR-16-1-3p levels below the median value in normal samples (P < 0.05). Finally, although no correlation was found between the expression of each miRNA and other clinicopathological features (Ki67, CD38, ZAP70, and IGVH@ hypermutations), the OS curves showed a positive trend in patients with miRNAs downregulation, though not statistically significant. In conclusion, we showed for the first time that all miRNAs can be successfully studied in FFPE CLL tissues and that del13q and PCs richness do not strictly correspond to miRNAs downregulation; therefore, a specific evaluation may be envisaged at least in patients enrolled in clinical trials.

Citing Articles

Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.

Saeed R, Abdulrahman Z, Mohammad D Saudi J Biol Sci. 2024; 31(7):104027.

PMID: 38831894 PMC: 11145380. DOI: 10.1016/j.sjbs.2024.104027.


Inside the chronic lymphocytic leukemia cell: miRNA and chromosomal aberrations.

Grenda A, Filip A, Wasik-Szczepanek E Mol Med Rep. 2022; 25(2).

PMID: 34981813 PMC: 8767551. DOI: 10.3892/mmr.2022.12581.


Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.

Filip A, Grenda A, Popek S, Koczkodaj D, Michalak-Wojnowska M, Budzynski M Ann Hematol. 2016; 96(1):33-50.

PMID: 27730344 PMC: 5203831. DOI: 10.1007/s00277-016-2840-6.


Absent MicroRNAs in Different Tissues of Patients with Acquired Cardiomyopathy.

Siegismund C, Rohde M, Kuhl U, Escher F, Schultheiss H, Lassner D Genomics Proteomics Bioinformatics. 2016; 14(4):224-34.

PMID: 27475403 PMC: 4996855. DOI: 10.1016/j.gpb.2016.04.005.

References
1.
Logan A, Gao H, Wang C, Sahaf B, Jones C, Marshall E . High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A. 2011; 108(52):21194-9. PMC: 3248502. DOI: 10.1073/pnas.1118357109. View

2.
Burke J, Swartz W, Brownell M, Brynes R, Hill L, Nathwani B . Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood. 1989; 73(2):579-87. View

3.
Juliusson G, Oscier D, Fitchett M, Ross F, Stockdill G, Mackie M . Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323(11):720-4. DOI: 10.1056/NEJM199009133231105. View

4.
Gao X, Zhang R, Qu X, Zhao M, Zhang S, Wu H . MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk Res. 2012; 36(12):1505-9. DOI: 10.1016/j.leukres.2012.08.021. View

5.
Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R . Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996; 92(2):382-8. DOI: 10.1046/j.1365-2141.1996.d01-1478.x. View